Please select an option
Please enter a valid email address
Please complete this field
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fund is dedicated to investing in intellectual property commercialisation.
We make UCL’s research physical and life sciences ideas happen.
Discover companies, licensing projects and proof-of-concepts backed by the Fund across Life Sciences and Physical Sciences. (Here listed only the publicly announced investments)
Biotech company developing novel cancer immunotherapies
Biotech company advancing a broad pipeline of potentially transformative therapeutic programs
Developing small molecule stabilisers to stabilise transthyretin in a rare, progressive disease called ATTR
Acquired company that created natural language processing technology to help machines answer questions.
Biotechnology company developing potentially curative treatments for patients suffering from rare neurological and metabolic diseases
Fuel cell company on a mission to help the world achieve net zero
Climate tech company using AI solutions to decarbonise cement and steel
Allogeneic stem cell derived therapy for the treatment of glaucoma
Medtech company developing, manufacturing and commercialising cardiovascular devices
Biotech company developing immunoglobulin E (IgE) antibodies to treat cancer
Biotech company focused on developing of liver-directed gene therapies for debilitating diseases, NASDAQ: FRLN
Company inventing and developing fast-charging batteries
Cell therapy for peripheral nerve repair
Novel drugs for the treatment of pancreatic cancer – partnered with Qualigen Therapeutics
AI company aiming to help developers and data scientists share information securely
Gene therapy targeting novel circuity for degenerative retinal diseases.
AI company creating tools allowing businesses to integrate natural language processing (NLP)
Develops a new type of all-silicon non-volatile memory
Augmented worker platform focused on improving quality and efficiency in production lines
Clinical-stage gene therapy company developing treatments for ocular diseases, NASDAQ: MGTX
Clinical-stage company developing autoregulatory bispecific antibody therapies to fight cancer
(Formerly Mediagamma) AI-powered eCommerce and advertising optimisation platform for Amazon
Company using AI to improve endoscopic procedures for better early detection and diagnosis of cancer
Engineered gamma delta (γδ) T cell platform for solid tumours.
Ex vivo lentiviral gene therapy company providing curative treatment for devastating inherited diseases, NASDAQ: ORTX
UCL spinout using light to train LLMs a hundred times faster with only a fraction of power
Software company simplifying graph analytics for businesses
Quantum computing company developing novel techniques to deliver real-world applications
Targeting LRG1 as a pathological regulator in a range of vascular diseases
AI startup leveraging active inference and the free energy principle to build ‘Agentic AI’ for the real world.
Developing cell therapy treatments for organ transplant patients and people with auto-immune conditions
EdTech platform connecting online maths tutors with pupils
Small molecule super-stabilisers of transthyretin for disease-modifying therapy in ATTR
Latest news and views from the team, companies and the UCL ecosystem.
UCLTF offers investment throughout the commercialisation journey. We fund proof-of-concept and development projects, and support founding teams with company formation.
